| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 7, 2021Nuvalent to present at AACR-NCI-EORTC Molecular Targets Conference
Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, provided new preclinical data on...
-
Sep 8, 2021Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial ResultsIND Application for NVL-520 Cleared by US FDA; Company Expects to Initiate Phase 1/2 Clinical Trial in Second Half of 2021
Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and...
-
Aug 2, 2021
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial...
-
Jul 28, 2021
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its initial public...
-
May 11, 2021Financing Led by Bain Capital Life Sciences – Andrew Hack, M.D., Ph.D., a Managing Director of Bain Capital Life Sciences, to Join Nuvalent Board of Directors
Cambridge, Mass., May 11, 2021 – Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a...
-
Apr 10, 2021Preclinical data presented at the 2021 AACR Annual Virtual Meeting supports advancement of parallel lead programs in ROS1-positive and ALK-positive NSCLC
Cambridge, Mass., April 10, 2021 – Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data...
-
Mar 23, 2021
Cambridge, Mass., March 23, 2021 – Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment...
-
Jan 27, 2021Company to advance parallel lead programs in ROS1-positive and ALK-positive NSCLC, expected to enter the clinic in 2H 2021 and 1H 2022, respectively
Cambridge, Mass., January 27, 2021 – Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced a $50M Series A...
The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.
